HTL 001
Alternative Names: HTL-001Latest Information Update: 28 Feb 2023
At a glance
- Originator HOX Therapeutics
- Class Antineoplastics; Peptides
- Mechanism of Action Homeodomain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Brain cancer
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Brain-cancer in United Kingdom (IV)
- 01 Feb 2019 HTL 001 is available for licensing as of 01 Feb 2019 (HOX Therapeutics website, January 2019)
- 29 Jan 2019 HOX Therapeutics plans a first-in-man phase I trial for Brain Cancer in 2019